PROACTIA is a prospective, event-driven observational study. It aims to propose a composite scoring system in order to evaluate the risk of paroxysmal atrial fibrillation (PAF) in patients after acute cryptogenic stroke and transient ischemic attack (TIA).
It will be enrolled 250 participants of both sexes within two weeks after diagnosed cryptogenic stroke and/or TIA at Akershus University Hospital, Oslo area, Norway.
Evaluation of participants' comorbidity with CHADS2-VASc score, ECG, Holter ECG, echocardiography, detection of biochemical cardiac markers and screening for obstructive sleep apnea syndrome will be performed. All participants will be monitored with a continuous cardiac rhythm during one year by implantation of implantable cardiac rhythm monitors (ICRM). All patients without high bleeding risk will get prescribed oral anticoagulants (OAC) after detection of PAF.
A biobank will be established in order to store the sampled biological material.
- Implantation of ICRM Device
Intervention Desc: All patients will be implanted with ICRM in order to detect an occult PAF. ARM 1: Kind: Experimental Label: Patients with cryptogenic stroke and TIA Description: Implantation of ICRM in all participants.
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
250 participants of both sexes included at Akershus University Hospital, Norway, within two weeks after diagnosed with cryptogenic stroke and/or TIA.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Detection of paroxysmal atrial fibrillation||One year||Yes|
Biospecimen Retention:Samples With DNA - Blood samples